Mavacamten特异性治疗肥厚型心肌病的研究进展

杨昭; 杨旭明; 杜来景

doi:10.13201/j.issn.1001-1439.2022.04.003

Mavacamten特异性治疗肥厚型心肌病的研究进展

- 河南科技大学第一附属医院心血管内科(河南洛阳，471003)

详细信息

通讯作者: 杨旭明, E-mail: 276664103@qq.com

中图分类号: R542.2

收稿日期: 2021-07-08

刊出日期: 2022-04-13

Research progress of Mavacamten in the treatment of hypertrophic cardiomyopathy

- Department of Cardiology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan, 471003, China

More Information

Corresponding author: YANG Xuming, E-mail: 276664103@qq.com

Received Date: 08 July 2021

Publish Date: 13 April 2022

摘要

摘要: Mavacamten是一种小分子肌球蛋白抑制剂，在治疗人类肥厚型心肌病(HCM)的潜在药物的筛选中被发现。Mavacamten可逆地抑制肌球蛋白与肌动蛋白的结合，抑制肌节力的产生，降低心肌高收缩性。临床试验也进一步证明其可以降低左心室流出道压力，减轻临床症状。现就Mavacamten的作用机制、临床价值及最新发现作一综述。
- 肥厚型心肌病 /
- 肌球蛋白调节剂 /
- 肌球蛋白 /
- 药物治疗
Abstract: Mavacamten is an allosteric inhibitor of sarcomeric myosins identified in a small-molecule screening of potential drugs for the treatment of human hypertrophic cardiomyopathy (HCM). Mavacamten reversibly inhibits the binding of myosin to actin, inhibits sarcomere force, and reduces myocardial hypercontractility. Clinical trials have further demonstrated that Mavacamten can reduce the left ventricular outflow tract (LOVT) pressure and alleviate the clinical symptoms of HCM. This paper reviews the mechanism of action, clinical application, and prospect of Mavacamten.
- hypertrophic cardiomyopathy /
- myosin modulator /
- myosin /
- pharmacological treatment

HTML全文

参考文献(33)

[1]	Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in(Young)Adults[J]. Circulation, 1995, 92(4): 785-789. doi: 10.1161/01.CIR.92.4.785
[2]	Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2015, 65(12): 1249-1254. doi: 10.1016/j.jacc.2015.01.019
[3]	Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2020, 142(25): e558-e631.
[4]	Spudich JA. Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations[J]. Pflugers Arch, 2019, 471(5): 701-717. doi: 10.1007/s00424-019-02259-2
[5]	Alsulami K, Marston S. Small Molecules acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases[J]. Int J Mol Sci, 2020, 21(24).
[6]	Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice[J]. Science, 2016, 351(6273): 617-621. doi: 10.1126/science.aad3456
[7]	Maron BJ, Maron MS. Hypertrophic cardiomyopathy[J]. Lancet, 2013, 381(9862): 242-255. doi: 10.1016/S0140-6736(12)60397-3
[8]	Force T, Bonow RO, Houser SR, et al. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute[J]. Circulation, 2010, 122(11): 1130-1133. doi: 10.1161/CIRCULATIONAHA.110.950089
[9]	Landstrom AP, Weisleder N, Batalden KB, et al. Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans[J]. J Mol Cell Cardiol, 2007, 42(6): 1026-1035. doi: 10.1016/j.yjmcc.2007.04.006
[10]	Ingles J, Doolan A, Chiu C, et al. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling[J]. J Med Genet, 2005, 42(10): e59. doi: 10.1136/jmg.2005.033886
[11]	Girolami F, Ho CY, Semsarian C, et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations[J]. J Am Coll Cardiol, 2010, 55(14): 1444-1453. doi: 10.1016/j.jacc.2009.11.062
[12]	林丽容, 卢荔红, 胡雪群, 等. 家族性肥厚型心肌病MYBPC3基因变异及其临床表型分析[J]. 临床心血管病杂志, 2021, 37(6): 557-560. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202106013.htm
[13]	Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers[J]. Proc Natl Acad Sci U S A, 2018, 115(35): E8143-E8152.
[14]	Spudich JA. Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases[J]. Biophys J, 2014, 106(6): 1236-1249. doi: 10.1016/j.bpj.2014.02.011
[15]	Lionne C, Brune M, Webb MR, et al. Time resolved measurements show that phosphate release is the rate limiting step on myofibrillar ATPases[J]. FEBS Lett, 1995, 364(1): 59-62. doi: 10.1016/0014-5793(95)00356-E
[16]	Toyoshima YY, Kron SJ, McNally EM, et al. Myosin subfragment-1 is sufficient to move actin filaments in vitro[J]. Nature, 1987, 328(6130): 536-539. doi: 10.1038/328536a0
[17]	Scellini B, Piroddi N, Dente M, et al. Mavacamten has a differential impact on force generation in myofibrils from rabbit psoas and human cardiac muscle[J]. J Gen Physiol, 2021, 153(7).
[18]	Nag S, Trivedi DV. To lie or not to lie: Super-relaxing with myosins[J]. Elife, 2021, 10: e63703. doi: 10.7554/eLife.63703
[19]	Nelson SR, Li A, Beck-Previs S, et al. Imaging ATP Consumption in Resting Skeletal Muscle: One Molecule at a Time[J]. Biophys J, 2020, 119(6): 1050-1055. doi: 10.1016/j.bpj.2020.07.036
[20]	Mamidi R, Li J, Doh CY, et al. Impact of the Myosin Modulator Mavacamten on Force Generation and Cross-Bridge Behavior in a Murine Model of Hypercontractility[J]. J Am Heart Assoc, 2018, 7(17): e009627. doi: 10.1161/JAHA.118.009627
[21]	Awinda PO, Bishaw Y, Watanabe M, et al. Effects of mavacamten on Ca²⁺ sensitivity of contraction as sarcomere length varied in human myocardium[J]. Br J Pharmacol, 2020, 177(24): 5609-5621. doi: 10.1111/bph.15271
[22]	Awinda PO, Watanabe M, Bishaw Y, et al. Mavacamten decreases maximal force and Ca²⁺ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy[J]. Am J Physiol Heart Circ Physiol, 2021, 320(2): H881-H890. doi: 10.1152/ajpheart.00345.2020
[23]	Sparrow AJ, Sievert K, Patel S, et al. Measurement of Myofilament-Localized Calcium Dynamics in Adult Cardiomyocytes and the Effect of Hypertrophic Cardiomyopathy Mutations[J]. Circ Res, 2019, 124(8): 1228-1239. doi: 10.1161/CIRCRESAHA.118.314600
[24]	Grillo MP, Erve J, Dick R, et al. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin[J]. Xenobiotica, 2019, 49(6): 718-733. doi: 10.1080/00498254.2018.1495856
[25]	Stern JA, Markova S, Ueda Y, et al. A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy[J]. PLoS One, 2016, 11(12): e0168407. doi: 10.1371/journal.pone.0168407
[26]	Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial[J]. Ann Intern Med, 2019, 170(11): 741-748. doi: 10.7326/M18-3016
[27]	Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2020, 75(21): 2649-2660. doi: 10.1016/j.jacc.2020.03.064
[28]	Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: A clinical trial[J]. Ann Intern Med, 2019, 170(11): 741-748. doi: 10.7326/M18-3016
[29]	Geske JB, McKie PM, Ommen SR, et al. B-type natriuretic peptide and survival in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2013, 61(24): 2456-2460. doi: 10.1016/j.jacc.2013.04.004
[30]	Seydelmann N, Liu D, Krämer J, et al. High-sensitivity troponin: A clinical blood biomarker for staging cardiomyopathy in Fabry disease[J]. J Am Heart Assoc, 2016, 5(6).
[31]	Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy(EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2020, 396(10253): 759-769. doi: 10.1016/S0140-6736(20)31792-X
[32]	Saberi S, Cardim N, Yamani M, et al. Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis[J]. Circulation, 2021, 143(6): 606-608. doi: 10.1161/CIRCULATIONAHA.120.052359
[33]	Desai MY, Wolski K, Owens A, et al. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy[J]. Am Heart J, 2021, 239: 80-89. doi: 10.1016/j.ahj.2021.05.007